The Indian pharmaceutical market grew 12% year-on-year in April-May 2026, well above the three-year quarterly average of 9%. Growth was led by oncology, anti-diabetic therapies (driven by GLP-1 drugs), cardiac, urology, vitamins, minerals and nutrients (VMN), and pain therapies, all of which expanded more than 12%.
Pharma Q1FY27 preview: Domestic strength to offset muted US growth
Date:
More like thisRelated
Buy or sell: Gift Nifty signals gap-down start, Vaishali Parekh recommends three stocks to buy today — 23 July 2026
स्टॉक खरीदें या बेचें, 23 जुलाई 2026: भारतीय शेयर...
US launches fresh strikes on Iran; Houthis claim attacks on Saudi tankers
US-Iran War Live Updates: Threats to oil shipments spread...
South Korea’s economy beats estimates as AI-related chip surge aids growth
In the second quarter, South Korea's economy expanded more...
IL&FS resolves over ₹57,500 crore worth of debt, nearing end of clean-up
Infrastructure Leasing & Financial Services (IL&FS) has filed its...